Baker Tilly co-authors clinical study for risk assessment tool in managing women at risk for ovarian cancer

Generating value-focused evidence in clinical studies is crucial for developing new and better care pathways for patients. Not only does it lead to improved patient care and quality of life, but a robust body of evidence helps payer and provider organizations make more informed decisions on coverage, reimbursement, accurate diagnoses, appropriate treatments to deliver, and reduction in unnecessary medical services. This also allows for the integration of value-based care treatments that are driven by solid clinical utility evidence that optimizes resource allocation, improves patient outcomes and enhances healthcare efficiency. 

As a part of Baker Tilly’s mission to help healthcare organizations on their journeys to optimizing care delivery, our team of healthcare specialists has co-authored a first-of-its-kind clinical utility study in the Journal of Comparative Effectiveness Research (JCER) demonstrating the value of risk assessment tools in managing women at risk for ovarian cancer. This study helps to demonstrate that following a new care pathway can lead to fewer tumor-removal surgeries that are often unnecessary and fewer referrals to gynecologic oncologists that are expensive and not readily accessible to many women. Baker Tilly was also able to demonstrate meaningful financial savings to payers and the broader healthcare system.  

Baker Tilly remains proud to support new women’s health initiatives designed to improve quality-of-life among its many focus areas, which include heart, orthopedic and gastroenterology health. For more information, read the Baker Tilly-co-authored paper, A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk.